{
  "abstract": "Objective Faecal immunochemical test (FIT) is widely used in colorectal cancer (CRC) screening, but the impact of antithrombotic therapy on colonoscopy outcomes remains unclear. This study aimed to compare polyp detection rate (PDR) and prevalence of non-neoplastic findings in FIT-positive patients undergoing colonoscopy, stratified by antithrombotic therapy.Methods We conducted a retrospective, multicentre cohort study of 26 280 FIT-positive colonoscopies performed between 2016 and 2023 across seven gastroenterology centres in Israel. The FIT positivity threshold was 75 ng/mL. Patients were grouped by therapy: antiplatelets (n=1904), anticoagulants (n=262) or no antithrombotic treatment (n=24 079). Using crude and matched analyses, we assessed PDR, adenoma detection rate (ADR), CRC detection and diverticulosis prevalence.Results Patients on antithrombotics were older (mean 65.9±7 vs 61.0±8 years; p<0.001), more often men (65.2% vs 50.1%; p<0.001) and had higher comorbidity rates. Crude PDR was higher in antithrombotic users (55.5% vs 51.9%; p=0.001), but ADR was similar (28.2% vs 28.3%; p=0.950). Diverticulosis was more prevalent in the antithrombotic group (24.0% vs 17.4%; p<0.001). After matching for age and sex (n=2201 pairs), all previously significant associations were eliminated: PDR were no longer different (55.5% vs 53.1%; p=0.112), diverticulosis prevalence became identical (24.0% vs 24.3%; p=0.799) and normal colonoscopy rates were similar (27.5% vs 29.6%; p=0.123). ADRs remained comparable (28.2% vs 26.7%; p=0.269), and CRC detection rates were identical (2.0% vs 2.0%; p=0.998).Conclusion Demographic confounding, rather than antithrombotic therapy per se, explains the crude associations in colonoscopy outcomes. The matched analysis demonstrates that antithrombotics do not independently affect polyp detection, diverticulosis prevalence or adenoma detection when age and sex are controlled for. These findings support the continued use of antithrombotics during CRC screening, shifting clinical interpretation from medication-based to demographic-based risk stratification.",
  "authors": [
    {
      "affiliations": [
        "Institute of Gastroenterology and Hepatology, Soroka University Medical Center, Beer Sheva, Israel, Israel"
      ],
      "name": "Naim Abu-Freha"
    },
    {
      "affiliations": [
        "Clalit Health Services, Tel Aviv-Yafo, Israel",
        "Family Medicine Department, Affula, Israel"
      ],
      "name": "Mifleh Tatour"
    },
    {
      "affiliations": [
        "Hillel Yaffe Medical Center, Hadera, Israel"
      ],
      "name": "Fadi Abu Baker"
    },
    {
      "affiliations": [
        "Gastroenterology Department, Rambam Health Care Campus, Haifa, Haifa District, Israel",
        "Technion Israel Institute of Technology, Haifa, Haifa District, Israel"
      ],
      "name": "Tarek Saadi"
    },
    {
      "affiliations": [
        "Assuta Medical Center, Haifa, Israel",
        "Bar-Ilan University, Ramat Gan, Tel Aviv District, Israel"
      ],
      "name": "Rawi Hazzan"
    }
  ],
  "title": "Impact of antithrombotic therapy on colonoscopy outcomes in FIT-positive patients: implications for polyp detection, diverticulosis and normal findings",
  "uid": "8ef7bd06-421c-545c-a77a-7ead1b84192e"
}